Curis, Inc. (CRIS)

Market Cap	9.56M -61.1%
Revenue (ttm)	9.44M -13.4%
Net Income	-7.58M
EPS	-0.58
Shares Out	12.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,249
Open	0.8000
Previous Close	0.7712
Day's Range	0.7330 - 0.8160
52-Week Range	0.7330 - 3.1300
Beta	2.98
Analysts	Strong Buy
Price Target	16.67 (+2,153.31%)
Earnings Date	Mar 19, 2026

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 1, 2000
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: CRIS
• Website: https://www.curis.com

Financial Performance

In 2025, Curis's revenue was $9.44 million, a decrease of -13.43% compared to the previous year's $10.91 million. Losses were -$7.58 million, -82.53% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price target is $16.67, which is an increase of 2,153.31% from the latest price.

Price Target

$16.67

(2,153.31% upside)

Analyst Consensus: Strong Buy